NZ504771A - IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF) - Google Patents

IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)

Info

Publication number
NZ504771A
NZ504771A NZ504771A NZ50477198A NZ504771A NZ 504771 A NZ504771 A NZ 504771A NZ 504771 A NZ504771 A NZ 504771A NZ 50477198 A NZ50477198 A NZ 50477198A NZ 504771 A NZ504771 A NZ 504771A
Authority
NZ
New Zealand
Prior art keywords
type
interferon
prolonging
infcomplex
ifnar2
Prior art date
Application number
NZ504771A
Other languages
English (en)
Inventor
Mark Tepper
Mark Cunningham
David Sherris
Tayar Nabil El
Sean Mckenna
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NZ504771A publication Critical patent/NZ504771A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ504771A 1997-12-19 1998-12-18 IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF) NZ504771A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (1)

Publication Number Publication Date
NZ504771A true NZ504771A (en) 2002-09-27

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504771A NZ504771A (en) 1997-12-19 1998-12-18 IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)

Country Status (27)

Country Link
US (1) US6372207B1 (enExample)
EP (1) EP1037658B1 (enExample)
JP (1) JP4601163B2 (enExample)
KR (1) KR100593981B1 (enExample)
CN (1) CN1241638C (enExample)
AR (1) AR020315A1 (enExample)
AT (1) ATE218362T1 (enExample)
AU (1) AU755078B2 (enExample)
BG (1) BG64920B1 (enExample)
BR (1) BR9813753A (enExample)
CA (1) CA2311648C (enExample)
DE (1) DE69805844T2 (enExample)
DK (1) DK1037658T3 (enExample)
EA (1) EA003635B1 (enExample)
EE (1) EE200000355A (enExample)
ES (1) ES2174530T3 (enExample)
HU (1) HUP0100456A3 (enExample)
IL (2) IL136855A0 (enExample)
NO (1) NO20002691L (enExample)
NZ (1) NZ504771A (enExample)
PL (1) PL197568B1 (enExample)
PT (1) PT1037658E (enExample)
SK (1) SK9222000A3 (enExample)
TR (1) TR200001961T2 (enExample)
UA (1) UA74132C2 (enExample)
WO (1) WO1999032141A1 (enExample)
ZA (1) ZA9811634B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
EP1666496B1 (en) * 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
EP2572734B1 (en) * 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINS AND NEUROANTIGENE FOR THE TREATMENT OF IMMUNE DISEASES
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
WO2014151422A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
CN111050803A (zh) * 2017-06-20 2020-04-21 德克萨斯大学系统董事会 用于治疗癌症的干扰素前药
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
JP4601163B2 (ja) 2010-12-22
PL197568B1 (pl) 2008-04-30
IL136855A (en) 2007-07-24
BG64920B1 (bg) 2006-09-29
BR9813753A (pt) 2000-10-10
PL341423A1 (en) 2001-04-09
CA2311648C (en) 2010-11-16
EP1037658A1 (en) 2000-09-27
EA003635B1 (ru) 2003-08-28
ATE218362T1 (de) 2002-06-15
AR020315A1 (es) 2002-05-08
AU1926999A (en) 1999-07-12
TR200001961T2 (tr) 2000-11-21
KR100593981B1 (ko) 2006-06-30
AU755078B2 (en) 2002-12-05
JP2001526242A (ja) 2001-12-18
HUP0100456A1 (hu) 2001-06-28
UA74132C2 (uk) 2005-11-15
DE69805844T2 (de) 2002-10-24
PT1037658E (pt) 2002-10-31
ZA9811634B (en) 1999-06-22
NO20002691D0 (no) 2000-05-25
CA2311648A1 (en) 1999-07-01
HK1032914A1 (en) 2001-08-10
DE69805844D1 (de) 2002-07-11
US6372207B1 (en) 2002-04-16
NO20002691L (no) 2000-08-18
WO1999032141A1 (en) 1999-07-01
BG104539A (en) 2001-04-30
CN1241638C (zh) 2006-02-15
HUP0100456A3 (en) 2003-09-29
KR20010032836A (ko) 2001-04-25
EE200000355A (et) 2001-10-15
ES2174530T3 (es) 2002-11-01
IL136855A0 (en) 2001-06-14
EA200000685A1 (ru) 2000-12-25
DK1037658T3 (da) 2002-09-30
EP1037658B1 (en) 2002-06-05
CN1282255A (zh) 2001-01-31
SK9222000A3 (en) 2001-01-18

Similar Documents

Publication Publication Date Title
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
ITMI951277A0 (it) Formulazioni di analoghi monomerici dell'insulina
ITMI951278A0 (it) Formulazioni di analoghi dell'insulina
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
ID28003A (id) Turunan-turunan adamantana
HUP0104574A3 (en) Analogues of glp-1, pharmaceutical compositions comprising thereof and their use
GB2365772A (en) Factor
NL300432I2 (en) Pharmaceutical composition comprising pioglitazoneand glimepiride for use in treatment of diabetes.
HUP0003592A3 (en) Lh-rh peptide analogues, their use and pharmaceutical compositions containing them
OA09736A (en) "Human interleukin-3 and muteins thereof".
GB9806632D0 (en) Peptide factor
GR3036625T3 (en) Oral delivery of chemically modified proteins
HUP9801256A3 (en) 5'-deoxy-cytidine derivatives, preparation and use thereof and pharmaceutical compositions
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
HRP950612B1 (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
IL119417A (en) Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
GB9700817D0 (en) Drug delivery composition for the nasal administration of antiviral agents
HUP0003207A3 (en) Proliposome powders for inhalation stabilised by tocopherol, pharmaceutical compositions containing the same and the use of them
HU9701080D0 (en) Pharmaceutical composition of antiviral activity
IL135723A (en) 1'-Ä4-Ä1-4-Fluorophenyl)-1H-indole-3-ylÜ-1-butylÜ-spiroÄisobenzofuran-1-(3H),4'-piperidineÜhydrohal ogenides and pharmaceutical compositions containing them
FR2718451B1 (fr) Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.

Legal Events

Date Code Title Description
PSEA Patent sealed
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: BY WAY OF CORRECTION

RENW Renewal (renewal fees accepted)
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: LABORATOIRES SERONO SA, CH

Free format text: OLD OWNER(S): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

RENW Renewal (renewal fees accepted)